These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy. Tamura T; Tasaka T; Fujimoto M; Matsuhashi Y; Fukumot T; Mano S; Kuwajima M; Nagai M Haematologica; 2004 Sep; 89(9):ECR32. PubMed ID: 15377484 [No Abstract] [Full Text] [Related]
9. Chronic myelogenous leukemia progenitors display a genetically unstable personality. Rodrigues MS; Sattler M J Natl Cancer Inst; 2007 May; 99(9):662-3. PubMed ID: 17470729 [No Abstract] [Full Text] [Related]
10. Chronic myeloid leukemia with a novel four-way t(6;13;9;22)(p21;q32;q34;q11.2) successfully treated with imatinib mesylate. Kubota Y; Waki M Cancer Genet Cytogenet; 2010 Sep; 201(2):135-6. PubMed ID: 20682400 [No Abstract] [Full Text] [Related]
11. The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism. Breccia M; Alimena G Leuk Res; 2009 Jul; 33(7):871-5. PubMed ID: 19307018 [TBL] [Abstract][Full Text] [Related]
12. Imatinib resistance in CML. Volpe G; Panuzzo C; Ulisciani S; Cilloni D Cancer Lett; 2009 Feb; 274(1):1-9. PubMed ID: 18653275 [TBL] [Abstract][Full Text] [Related]
14. Managing relapse of CML using therapeutic imatinib plasma level. Onitilo AA; Engel JM Clin Adv Hematol Oncol; 2009 Nov; 7(11):763-7. PubMed ID: 20075835 [No Abstract] [Full Text] [Related]
15. Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors? Maziarz RT Curr Opin Hematol; 2008 Mar; 15(2):127-33. PubMed ID: 18300759 [TBL] [Abstract][Full Text] [Related]
16. Gelatinous transformation of bone marrow in chronic myeloid leukemia during treatment with imatinib mesylate: a disease or a drug effect? Ram R; Gafter-Gvili A; Okon E; Pazgal I; Shpilberg O; Raanani P Acta Haematol; 2008; 119(2):104-7. PubMed ID: 18367829 [TBL] [Abstract][Full Text] [Related]
17. Resolution of rheumatoid arthritis symptoms with imatinib mesylate. Vernon MR; Pearson L; Atallah E J Clin Rheumatol; 2009 Aug; 15(5):267. PubMed ID: 19654496 [No Abstract] [Full Text] [Related]
18. Bone marrow with gelatinous transformation associated with residual disease in imatinib mesylate-treated chronic myelogenous leukaemia (CML). Thakral B; Higa B; Venkataraman G; Velankar MM Pathology; 2012 Jan; 44(1):59. PubMed ID: 22157697 [No Abstract] [Full Text] [Related]
19. Imatinib and regression of type 2 diabetes. Veneri D; Franchini M; Bonora E N Engl J Med; 2005 Mar; 352(10):1049-50. PubMed ID: 15758023 [No Abstract] [Full Text] [Related]
20. Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation. Potenza L; Volzone F; Riva G; Soverini S; Martinelli S; Iacobucci I; Gnani A; Barozzi P; Forghieri F; Morselli M; Zanetti E; Maccaferri M; Baccarani M; Martinelli G; Torelli G; Luppi M Br J Haematol; 2009 Jul; 146(2):227-30. PubMed ID: 19545285 [No Abstract] [Full Text] [Related] [Next] [New Search]